Epidemiological and molecular characterization of HBV and HCV infections in HIV-1-infected inmate population in Italy: a 2017-2019 multicenter cross-sectional study.

Humans Cross-Sectional Studies HIV-1 / genetics Hepatitis B virus / genetics Coinfection / epidemiology Phylogeny HIV Seropositivity Hepatitis C / complications Italy / epidemiology

Journal

Scientific reports

ISSN: 2045-2322

Titre abrégé: Sci Rep

Pays: England

ID NLM: 101563288

Informations de publication

Date de publication:
09 09 2023

Historique:

received: 14 03 2023

accepted: 31 08 2023

medline: 11 9 2023

pubmed: 10 9 2023

entrez: 9 9 2023

Statut: epublish

Résumé

HBV/HCV co-infection is common in HIV-1-infected prisoners. To investigate the characteristics of HIV co-infections, and to evaluate the molecular heterogeneity of HIV, HBV and HCV in prisoners, we carried-out a multicenter cross-sectional study, including 65 HIV-1-infected inmates enrolled in 5 Italian detention centers during the period 2017-2019. HIV-1 subtyping showed that 77.1% of inmates were infected with B subtype and 22.9% with non-B subtypes. Italian nationals were all infected with subtype B (93.1%), except two individuals, one infected with the recombinant form CRF72_BF1, and the other with the HIV-1 sub-subtype A6, both previously not identified in inmates of Italian nationality. Non-Italian nationals were infected with subtype B (52.6%), CRFs (36.8%) and sub-subtypes A1 and A3 (5.2%). HIV variants carrying resistance mutations to NRTI, NNRTI, PI and InSTI were found in 7 inmates, 4 of which were never exposed to the relevant classes of drugs associated with these mutations. HBV and/or HCV co-infections markers were found in 49/65 (75.4%) inmates, while 27/65 (41.5%) showed markers of both HBV and HCV coinfection. Further, Italian nationals showed a significant higher presence of HCV markers as compared to non-Italian nationals (p = 0.0001). Finally, HCV phylogenetic analysis performed in 18 inmates revealed the presence of HCV subtypes 1a, 3a, 4d (66.6%, 16.7% and 16.7%, respectively). Our data suggest the need to monitor HIV, HBV and HCV infections in prisons in order to prevent spreading of these viruses both in jails and in the general population, and to implement effective public health programs that limit the circulation of different genetic forms as well as of viral variants with mutations conferring resistance to treatment.

Identifiants

DOI: 10.1038/s41598-023-41814-x PMID: 37689795 PMC: PMC10492787

pubmed: 37689795

doi: 10.1038/s41598-023-41814-x

pii: 10.1038/s41598-023-41814-x

pmc: PMC10492787

doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

14908

Informations de copyright

Références

Dolan, K. et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet 388, 1089–1102 (2016).

doi: 10.1016/S0140-6736(16)30466-4

Dolan, K. et al. HIV in prison in low-income and middle-income countries. Lancet Infect. Dis. 7, 32–41 (2007).

pubmed: 17182342 doi: 10.1016/S1473-3099(06)70685-5

Babudieri, S. B. et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: Results from a multicentre study in Italy. J. Med. Virol. 76, 311–317 (2005).

pubmed: 15902712 doi: 10.1002/jmv.20375

Maggiorella, M. T. et al. Italian network for HIV characterization. High HIV-1 diversity in immigrants resident in Italy (2008–2017). Sci. Rep. 10, 3226 (2020).

pubmed: 32094387 pmcid: 7039940 doi: 10.1038/s41598-020-59084-2

Lai, A. et al. Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. HIV Med. 11, 593–602 (2010).

pubmed: 20408891 doi: 10.1111/j.1468-1293.2010.00832.x

Ciccozzi, M. et al. HIV-1 non-B subtypes in Italy: A growing trend. New Microbiol. 5, 377–386 (2012).

Lorenzin, G. et al. Prevalence of non-B HIV-1 subtypes in North Italy and analysis of transmission clusters based on sequence data analysis. Microorganisms. 23;8(1), 36 (2019).

Sarmati, L. & Malagnino, V. HBV infection in HIV-driven immune suppression. Viruses 11, 1077 (2019).

pubmed: 31752284 pmcid: 6893694 doi: 10.3390/v11111077

Merchante, N., Jiménez-Saenz, M. & Pineda, J. A. Management of HCV-related end-stage liver disease in HIV-coinfected patients. AIDS Rev. 9, 131–139 (2007).

pubmed: 17982938

Kim, H. N. et al. Treatment of HCV in Persons with HIV Coinfection. Hepatitis C Online. https://www.hepatitisc.uw.edu/go/key-populations-situations/treatment-hiv-coinfection/core-concept/all . Last updated: February 17th (2021).

Moron- Lopez, S. et al. Short-term treatment with interferon alfa diminishes expression of HIV-1 and reduces CD4+ T-cell activation in patients coinfected with HIV and hepatitis C virus and receiving antiretroviral therapy. J. Infect. Dis. 213(6), 1008–12 (2016).

pubmed: 26525407 doi: 10.1093/infdis/jiv521

Curry, M. P. HIV and hepatitis C virus: Special concerns for patients with cirrhosis. J. Infect. Dis. 207, 40–44 (2013).

doi: 10.1093/infdis/jis763

Platt, L. et al. Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis. J. Viral Hepat. 27, 294–315 (2019).

pubmed: 31603999 pmcid: 7383613 doi: 10.1111/jvh.13217

Platt, L., Easterbrook, P., Gower, E., McDonald, B. & Sabin, K. Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis. Lancet Infect. Dis. 16, 797–808 (2016).

pubmed: 26922272 doi: 10.1016/S1473-3099(15)00485-5

Bick, J. A. Infection control in jails and prisons. Clin. Infect. Dis. 45, 1047–1055 (2007).

pubmed: 17879924 doi: 10.1086/521910

Falla, A. M. et al. Hepatitis B/C in the countries of the EU/EEA: A systematic review of the prevalence among at-risk groups. BMC Infect. Dis. 18, 79 (2018).

pubmed: 29433454 pmcid: 5809955 doi: 10.1186/s12879-018-2988-x

Ahmadi Gharaei, H. et al. The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: A systematic review and meta-analysis. Infect. Dis. Poverty 10, 93 (2021).

pubmed: 34210349 pmcid: 8252262 doi: 10.1186/s40249-021-00876-7

Sagnelli, E. et al. Blood born viral infections, sexually transmitted diseases and latent tuberculosis in italian prisons: A preliminary report of a large multicenter study. Eur. Rev. Med. Pharmacol. Sci. 16, 2142–2146 (2012).

pubmed: 23280032

Stasi, C., Silvestri, C., Fanti, E., Di Fiandra, T. & Voller, F. Prevalence and features of chronic viral hepatitis and HIV coinfection in Italian prisons. Eur. J. Intern. Med. 34, 21–22 (2016).

doi: 10.1016/j.ejim.2016.04.020

Pontali, E. et al. Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy. Int. J. Drug Policy 59, 50–53 (2018).

pubmed: 29986272 doi: 10.1016/j.drugpo.2018.06.017

Zuccaro, O. et al. Clinical, epidemiological and virological features of acute hepatitis B in Italy. Infection 43, 431–441 (2015).

pubmed: 25697541 doi: 10.1007/s15010-015-0747-0

Coppola, N. et al. Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. J. Viral Hepat. 17, 493–500 (2010).

pubmed: 19780943

Sagnelli, E., Sagnelli, C., Pisaturo, M., Macera, M. & Coppola, N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J. Gastroenterol. 20, 7635–7643 (2014).

pubmed: 24976701 pmcid: 4069292 doi: 10.3748/wjg.v20.i24.7635

Quaranta, M. G. et al. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Dig. Liver Dis. 53, 1603–1609 (2021).

pubmed: 33893040 doi: 10.1016/j.dld.2021.03.020

Babudieri, S. et al. HIV e infezioni correlate negli Istituti Penitenziari Italiani: Note di epidemiologia e di organizzazione sanitaria. Ann. Ist Super. Sanità 39, 251–257 (2003).

pubmed: 14587225

Dell’Isola, S. et al. Detention and incompatibility of HIV patients in Italy. Ann. Ist Super. Sanità 49, 332–333 (2013).

pubmed: 24334775

Hemelaar, J. et al. Global and regional epidemiology of HIV-1 recombinants in 1990–2015: A systematic review and global survey. Lancet HIV 7, 772–781 (2020).

doi: 10.1016/S2352-3018(20)30252-6

Hemelaar, J. et al. Country level diversity of the HIV-1 pandemic between 1990 and 2015. J. Virol. 95, e01580-e1620 (2020).

pubmed: 33087461 pmcid: 7944450 doi: 10.1128/JVI.01580-20

Bbosa, N., Kaleebu, P. & Ssemwanga, D. HIV subtype diversity worldwide. Curr. Opin. HIV AIDS 14, 153–160 (2019).

pubmed: 30882484 doi: 10.1097/COH.0000000000000534

Longo, B. et al. HIV-1 diversity among inmates of Italian Prisons. J. Med. Virol. 80, 1689–1694 (2008).

pubmed: 18712824 doi: 10.1002/jmv.21275

Sanarico, N. et al. Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study. Medicine (Baltimore) 95, e5257 (2016).

pubmed: 27858889 doi: 10.1097/MD.0000000000005257

Pessôa, R., De Freitas Carneiro Proietti, A. B., Busch, M. P. & Sanabani, S. S. Identification of a novel HIV-1 circulating recombinant form (CRF72_BF1) in deep sequencing data from blood donors in Southeastern Brazil. Genome Announc. 2, e00386-14 (2014).

pubmed: 24926043 pmcid: 4056286 doi: 10.1128/genomeA.00386-14

Abidi, S.H. et al. Origin and evolution of HIV-1 subtype A6. Plos One. 16 (2021).

Giovanetti, M., Ciccozzi, M., Parolin, C. & Borsetti, A. Molecular epidemiology of HIV-1 in African countries: A comprehensive overview. Pathogens 9(12), 1072 (2020).

pubmed: 33371264 pmcid: 7766877 doi: 10.3390/pathogens9121072

Pessoa, R. et al. Deep sequencing of HIV-1 near full-length proviral genomes identifies high rates of BF1 recombinants including two novel circulating recombinant forms (CRF) 70_BF1 and a disseminating 71_BF1 among blood donors in Pernambuco, Brazil. PLOS ONE 9, 11 (2014).

doi: 10.1371/journal.pone.0112674

Cañada, J. E. et al. Identification of a new HIV-1 BC intersubtype circulating recombinant form (CRF108_BC) in Spain. Viruses 13, 93 (2021).

pubmed: 33445523 pmcid: 7826730 doi: 10.3390/v13010093

Kim, M. H. et al. HIV antiretroviral resistance mutations among antiretroviral treatment-naive and -experienced patients in South Korea. AIDS Res. Hum. Retrovir. 29, 1617–1620 (2013).

pubmed: 23952717 pmcid: 3848436 doi: 10.1089/aid.2013.0184

Frentz, D. et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect. Dis. 14, 407 (2014).

pubmed: 25047543 pmcid: 4223652 doi: 10.1186/1471-2334-14-407

Jiamsakul, A. et al. Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007–2010)—TASER-S. AIDS Res. Ther. 12, 3 (2015).

pubmed: 25685169 pmcid: 4326480 doi: 10.1186/s12981-015-0043-1

Alexiev, I. et al. Low HIV-1 transmitted drug resistance in Bulgaria against a background of high clade diversity. J. Antimicrob. Chemother. 70, 1874–1880 (2015).

pubmed: 25652746 doi: 10.1093/jac/dkv011

Ndashimye, E., Reyes, P. S. & Arts, E. J. New antiretroviral inhibitors and HIV-1 drug resistance: More focus on 90% HIV-1 isolates?. FEMS Microbiol. Rev. 16(47), 1–22 (2023).

Pitman, M. C., Lau, J. S. Y., McMahon, J. H. & Lewin, S. R. Barriers and strategies to achieve a cure for HIV. Lancet HIV 5, e317–e328 (2018).

pubmed: 29893245 pmcid: 6559798 doi: 10.1016/S2352-3018(18)30039-0

Baxter, J. D. et al. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 16, 77–87 (2015).

pubmed: 25711326 pmcid: 4341921 doi: 10.1111/hiv.12236

Gupta, R. K. et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis. Lancet Infect. Dis. 18, 346–355 (2017).

pubmed: 29198909 doi: 10.1016/S1473-3099(17)30702-8

Bandera, A. et al. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. Curr. Opin. Pharmacol. 48, 24–32 (2019).

pubmed: 31029861 doi: 10.1016/j.coph.2019.03.003

Chen, Q. et al. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antivir. Res. 174, 104694 (2020).

pubmed: 31857134 doi: 10.1016/j.antiviral.2019.104694

Borghetti, A. et al. Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors. HIV Med. 22, 22–27 (2021).

pubmed: 32964671 doi: 10.1111/hiv.12956

Quashie, P. K. et al. Characterization of the R263K mutation in HIV-1 Integrase that confers low-level resistance to the second-generation Integrase strand transfer inhibitor Dolutegravir. J. Virol. 86, 2696–2705 (2012).

pubmed: 22205735 pmcid: 3302270 doi: 10.1128/JVI.06591-11

Garrido, C. et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob. Agents Chemother. 56, 2873–2878 (2012).

pubmed: 22450969 pmcid: 3370736 doi: 10.1128/AAC.06170-11

Doyle, T. et al. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J. Antimicrob. Chemother. 70, 3080–3086 (2015).

pubmed: 26311843 pmcid: 4613743 doi: 10.1093/jac/dkv243

De Francesco, M. A. et al. Prevalence of integrase strand transfer inhibitors resistance mutations in integrase strand transfer inhibitors-naive and -experienced HIV-1 infected patients: A single center experience. AIDS Res. Hum. Retrovir. 34, 570–574 (2018).

pubmed: 29631420 doi: 10.1089/aid.2018.0006

Alvarez, M. et al. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: Implications for clinical practice. J. Antimicrob. Chemother. 74, 1693–1700 (2019).

pubmed: 30838386 doi: 10.1093/jac/dkz067

Lepik, K. J. et al. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS 31, 1425–1434 (2017).

pubmed: 28375875 doi: 10.1097/QAD.0000000000001494

Van Herck, K., Leuridan, E. & Van Damme, P. Schedules for hepatitis B vaccination of risk groups: Balancing immunogenicity and compliance. Sex. Transm. Infect. 83, 426–432 (2007).

pubmed: 17911142 pmcid: 2598703 doi: 10.1136/sti.2006.022111

Stasi, C. et al. Screening for hepatitis B virus and accelerated vaccination schedule in prison: A pilot multicenter study. Vaccine 37, 1412–1417 (2019).

pubmed: 30733091 doi: 10.1016/j.vaccine.2019.01.049

Chang, J. J., Mohtashemi, N. & Bhattacharya, D. Significance and management of isolated hepatitis B core antibody (anti-HBc) in HIV and HCV: Strategies in the DAA era. Curr. HIV/AIDS Rep. 15, 172–181 (2018).

pubmed: 29572624 pmcid: 6039383 doi: 10.1007/s11904-018-0379-y

Wu, T., Kwok, R. M. & Tran, T. T. Isolated anti-HBc: The relevance of hepatitis B core antibody—A review of new issues. Am. J. Gastroenterol. 112, 1780–1788 (2017).

pubmed: 29087395 doi: 10.1038/ajg.2017.397

Stroffolini, T. et al. Hepatitis C virus infection among drug addicts in Italy. J. Med. Virol. 84, 1608–1612 (2012).

pubmed: 22930509 doi: 10.1002/jmv.23370

Gardini, I., Bartoli, M., Conforti, M., Mennini, F. S. & Marcellusi, A. Estimation of the number of HCV-positive patients in Italy. PLoS ONE 14, e0223668 (2019).

pubmed: 31671120 pmcid: 6822946 doi: 10.1371/journal.pone.0223668

Kondili, L. A. et al. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. Epidemics 34, 100442 (2021).

pubmed: 33607538 doi: 10.1016/j.epidem.2021.100442

Schmidt, J., Blum, H. E. & Thimme, R. T-cell responses in hepatitis B and C virus infection: Similarities and differences. Emerg. Microbes Infect. 2, e15 (2013).

pubmed: 26038456 pmcid: 3630955 doi: 10.1038/emi.2013.14

Giuliani, R. et al. HCV micro-elimination in two prisons in Milan, Italy: A model of care. J. Viral Hepat. 27, 1444–1454 (2020).

pubmed: 32815623 doi: 10.1111/jvh.13376

Rodríguez-Tajes, S. et al. Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. J. Gastroenterol. Hepatol. 35, 1570–1578 (2020).

pubmed: 31957902 doi: 10.1111/jgh.14984

Fiore, V. et al. Chronic viral hepatitis in the Italian prison setting: Prevalence, outcomes, literature needs and perspectives. Healthcare 9, 1186 (2021).

pubmed: 34574960 pmcid: 8467805 doi: 10.3390/healthcare9091186

Tresó, B. et al. Molecular epidemiology of hepatitis C virus genotypes and subtypes among injecting drug users in Hungary. Euro Surveill. 18, 20639 (2013).

pubmed: 24300886 doi: 10.2807/1560-7917.ES2013.18.47.20639

Salemovic, D. et al. Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Arch. Med. Sci. 13, 652–658 (2017).

pubmed: 28507583 pmcid: 5420631 doi: 10.5114/aoms.2017.66022

Tyczyno, M., Halota, W., Nowak, W. & Pawlowska, M. Distribution of HCV genotypes in the populations of inmates in polish prison Potulice and patients hospitalised in Bydgoszcz. Hepat. Mon. 14, e14559 (2014).

pubmed: 24910703 pmcid: 4030260 doi: 10.5812/hepatmon.14559

Petruzziello, A. et al. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS ONE 14, e0212033 (2019).

pubmed: 30785909 pmcid: 6382136 doi: 10.1371/journal.pone.0212033

Bon, I. et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV1 patients. J. Clin. Virol. 38, 313–320 (2007).

pubmed: 17306618 doi: 10.1016/j.jcv.2006.12.018

Kwon, E. H. et al. HIV-1 subtypes and drug resistance mutations among female sex workers varied in different cities and regions of the Democratic Republic of Congo. PLoS ONE 15, e0228670 (2020).

pubmed: 32045455 pmcid: 7012409 doi: 10.1371/journal.pone.0228670

Chew, C. B. et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J. Clin. Virol. 33, 206–216 (2005).

pubmed: 15911442 doi: 10.1016/j.jcv.2004.11.006

Arias, A. et al. Sanger and next generation sequencing approaches to evaluate HIV-1 virus in blood compartments. Int. J. Environ. Res. Public Health 15, 1697 (2018).

pubmed: 30096879 pmcid: 6122037 doi: 10.3390/ijerph15081697

Manyana, S. et al. HIV-1 drug resistance genotyping in resource limited settings: Current and future perspectives in sequencing technologies. Viruses 13(6), 1125 (2021).

pubmed: 34208165 pmcid: 8230827 doi: 10.3390/v13061125

Fokam, J. et al. Performance evaluation of an in house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch. Virol. 156, 1235–1243 (2011).

pubmed: 21465085 doi: 10.1007/s00705-011-0982-3

Giovanetti, M. et al. Analysis of HIV-1 integrase genotypes and polymorphisms among integrase inhibitors-based antiretroviral treatment naïve patients in South Sudan. J. Med. Virol. 94, 3320–3327 (2022).

pubmed: 35277871 doi: 10.1002/jmv.27713

Pybus, O. G. et al. Genetic history of hepatitis C virus in East Asia. J. Virol. 83, 1071–1082 (2009).

pubmed: 18971279 doi: 10.1128/JVI.01501-08

Hall, T. A. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41, 95–98 (1999).

Nei, M. & Kumar, S. Molecular Evolution and Phylogenetics (Oxford University Press, 2000).

doi: 10.1093/oso/9780195135848.001.0001

Bennett, D. E. et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4, e4724 (2009).

pubmed: 19266092 pmcid: 2648874 doi: 10.1371/journal.pone.0004724

Wensing, A. M. et al. 2019 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 27, 111–121 (2019).

pubmed: 31634862 pmcid: 6892618